Back to top
more

AVEO Pharmaceuticals, Inc. (AVEO)

(Delayed Data from NSDQ)

$0.94 USD

0.94
1,186,754

+0.04 (4.01%)

Updated May 3, 2019 04:00 PM ET

After-Market: $0.91 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 18.75% and 19.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Can Humana (HUM) Sustain Its Earnings Beat Streak in Q3?

by Zacks Equity Research

Humana's (HUM) Q3 results are expected to reflect growing premiums, attributable to its Medicare Advantage and Medicaid businesses. However, elevated marketing costs might have strained its margins.

BioNTech (BNTX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On BioNTech's (BNTX) third-quarter earnings call, investors will likely focus on the sales performance of its COVID-19 vaccine Comirnaty, developed in partnership with Pfizer.

AVEO Oncology (AVEO) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

AVEO Oncology's (AVEO) third-quarter earnings is expected to reflect strong Fotivda sales. The company is likely to beat the Zacks Consensus Estimate.

Mind Medicine (MNMD) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Mind Medicine MindMed (MNMD) is expected to provide an update on its pipeline candidates in its third-quarter earnings.

Agenus (AGEN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Agenus' (AGEN) third-quarter earnings call, investor focus is likely to be on the company's progress with the developments of its pipeline candidates.

Assertio (ASRT) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Assertio Holdings' (ASRT) third-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.

Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?

by Zacks Equity Research

Here is how AVEO Pharmaceuticals (AVEO) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.

Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

AVEO Pharmaceuticals (AVEO) Inks Deal to be Acquired by LG Chem

by Zacks Equity Research

Aveo Pharmaceuticals (AVEO) is set to be acquired by LG Chem for an aggregate amount of $566 billion. The deal is expected to close by early 2023. Stock up.

Zacks.com featured highlights Par Pacific, AVEO Pharmaceuticals and Heritage Commerce

by Zacks Equity Research

Par Pacific, AVEO Pharmaceuticals and Heritage Commerce have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

3 Breakout Stocks to Keep an Eye on for Solid Returns

by Tirthankar Chakraborty

Par Pacific (PARR), AVEO Pharmaceuticals (AVEO) and Heritage Commerce Corp (HTBK) have been selected as the breakout stocks for today.

Is AVEO Pharmaceuticals (AVEO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how AVEO Pharmaceuticals (AVEO) and Trevi Therapeutics, Inc. (TRVI) have performed compared to their sector so far this year.

Here's What Could Help AVEO (AVEO) Maintain Its Recent Price Strength

by Zacks Equity Research

AVEO (AVEO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

MaxCyte, Inc. (MXCT) Moves 9.3% Higher: Will This Strength Last?

by Zacks Equity Research

MaxCyte, Inc. (MXCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks.com featured highlights include Terns Pharmaceuticals, Napco Security Technologies and AVEO

by Zacks Equity Research

Terns Pharmaceuticals, Napco Security Technologies and AVEO have been highlighted in this Screen of The Week article.

Benjamin Rains headshot

Fight Back Against Inflation with New Analyst Coverage

by Benjamin Rains

Check out this new analyst coverage screen to help investors find stocks that are gaining more attention from Wall Street analysts that could be potential winners in the fourth quarter of 2022 and beyond.

Shrabana Mukherjee headshot

New Analysts Initiate Coverage: 3 Top-Ranked Stocks to Buy

by Shrabana Mukherjee

Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Terns Pharmaceuticals (TERN), Napco Security (NSSC) and AVEO.

Is AVEO Pharmaceuticals (AVEO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AVEO Pharmaceuticals (AVEO) and Trevi Therapeutics, Inc. (TRVI) have performed compared to their sector so far this year.

AVEO (AVEO) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, AVEO (AVEO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks.com featured highlights include Tsakos Energy, AVEO Pharmaceuticals and Catalyst Pharmaceuticals

by Zacks Equity Research

Tsakos Energy, AVEO Pharmaceuticals and Catalyst Pharmaceuticals have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

Buy These 3 Top Breakout Stocks Now for Superb Returns

by Tirthankar Chakraborty

Tsakos Energy Navigation (TNP), AVEO Pharmaceuticals (AVEO) and Catalyst Pharmaceuticals (CPRX) have been selected as the breakout stocks for today.

Ligand (LGND) Down 12% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shrabana Mukherjee headshot

5 Top Stocks to Buy on New Analysts' Coverage

by Shrabana Mukherjee

Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Napco Security (NSSC), Proto Labs (PRLB), Clear Secure (YOU), AVEO and Mind Medicine (MNMD).

Here's Why AVEO Pharmaceuticals (AVEO) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does AVEO Pharmaceuticals (AVEO) have what it takes to be a top stock pick for momentum investors? Let's find out.